The Genetic Basis for Atrial Fibrillation

NCT03491202 | Unknown

• 1 other identifier: 977544
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Atrial fibrillation (AF) is reaching epidemic proportions in the aging U.S. and European populations, but the mechanisms of increased susceptibility to atrial fibrillation are still unknown. In this study, we look to further examine genetic and medical co-morbidity influence of atrial fibrillation duration and response to medications. In Specific Aim 1, we propose the creation of a Veterans Affairs AF Biorepository (VAAFBio), which is a resource that will collect and store clinical, demographic, blood and DNA samples from patients with atrial fibrillation to aide this study and future studies of this type in the VA population. In Specific Aim 2, examine common genetic polymorphisms in veteran patients with atrial fibrillation and examine gene-environment interactions with risk factors for atrial fibrillation.

Conditions

Atrial Fibrillation

Outcome Measures

Primary Outcomes (2)

• Symptoms related to atrial fibrillation (chest pain, dyspnea, palpitations)

  1 year

• heart rate

  1 year

Study Arms (1)

atrial fibrillation

Patients with a diagnosis of atrial fibrillation will be eligible for enrollment

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients will be identified in the outpatient clinic or in the inpatient setting at the Jesse Brown VA Medical Center and approached for informed consent and HIPAA authorization.

You may qualify if:

• Subjects must be at least 18 years of age, and up to 100.
• Subjects must have a documented history of atrial fibrillation by ECG, ECHO, and or Holter monitor event recorder.
• Subjects must be willing to give written, informed consent.

You may not qualify if:

• Patients with a history of AF or atrial flutter that is only associated with cardiac surgery will be excluded from the study.
• Subjects who cannot speak English will be excluded from the study.

Sponsors & Collaborators

• Jesse Brown VA Medical Center: lead

Study Sites (1)

Jesse Brown VA Medical Center

Chicago, Illinois, 60612, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Katherine A Durham, APN

CONTACT

3125696635; Katherine.durham@va.gov

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: FED
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Cardiology Nurse Practitioner

Study Record Dates

• First Submitted: April 2, 2018
• First Posted: April 9, 2018
• Study Start: May 25, 2017
• Primary Completion: May 1, 2022
• Study Completion: May 1, 2022
• Last Updated: June 11, 2018

Record last verified: 2018-06

Locations

US (1)